Search Within

Debra Marion Sarasohn

Formats
  1. Journal Article (31)
  2. Meeting Abstract (17)
Groups
  1. Body Imaging Service (48)
  2. Radiology, Department of (48)
  3. Department of Medicine (30)
  4. Hematologic Malignancies, Division of (26)
  5. Gynecology Disease Management Team (22)
  6. Biostatistics Service (21)

More Groups

People
  1. Dennis Chi (14)
  2. Craig Moskowitz (12)
  3. Yukio Sonoda (12)
  4. Carol Portlock (11)
  5. Nadeem Abu-Rustum (11)
  6. Paul Hamlin (11)

More People

Years
  1. 2024 (1)
  2. 2023 (5)
  3. 2021 (1)
  4. 2020 (5)
  5. 2019 (3)
  6. 2018 (3)

More Years

Publications
  1. Gynecologic Oncology (12)
  2. Blood (7)
  3. American Journal of Roentgenology (6)
  4. Journal of Clinical Oncology (4)
  5. British Journal of Haematology (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. Elsevier Inc. (14)
  2. American Society of Hematology (7)
  3. American Roentgen Ray Society (6)
  4. American Society of Clinical Oncology (4)
  5. American Association for Cancer Research (3)
  6. John Wiley & Sons (3)

More Publishers

Results (48)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller
    Journal Article

    Chi, D. S.; Barlin, J. N.; Ramirez, P. T.; Levenback, C. F.; Mironov, S.; Sarasohn, D. M.; Iyer, R. B.; Dao, F.; Hricak, H.; Barakat, R. R.
    International Journal of Gynecological Cancer (2010)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Journal Article

    O'Connor, O. A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C. H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Correlation of pelvic MRI with final surgical specimen and outcome for patients with stage IB1 cervical carcinoma eho undergo a fertility-sparing radical trachelectomy
    Meeting Abstract

    Diaz, J. P.; Parbhu, R.; Alchyib, O.; Sonoda, Y.; Chi, D. S.; Barakat, R. R.; Sarasohn, D.; Abu-Rustum, N. R.
    Gynecologic Oncology (2009)

    Fulltext@MSK | Save
  • Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
    Journal Article

    O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Zelenetz, A. D.; Zhang, Z.; Dumitrescu, O.; Sarasohn, D.; Lin, D.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Moskowitz, C.; Portlock, C.; Sarasohn, D.; Dumitrescu, O.; Neylon, E.; Patterson, M.; Zelenetz, A.; Saunders, M.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • A prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease ≤ 1 cm
    Meeting Abstract

    Chi, D. S.; Barakat, R. R.; Ramirez, P. T.; Teitcher, J. B.; Mironov, S.; Sarasohn, D. M.; Iyer, R.; Abu-Rustum, N. R.; Sonoda, Y.; Hricak, H.
    Gynecologic Oncology (2007)

    Fulltext@MSK | Save
  • Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma
    Journal Article

    O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
    British Journal of Haematology (2007)

    Fulltext@MSK | Save